US Veterans Seek Ayahuasca Retreats Abroad: Policy and Access Gaps

Dozens of US Veterans Pursue Ayahuasca Therapy in Costa Rica

Forty-six American veterans and first responders recently traveled to a Costa Rican retreat to participate in ayahuasca ceremonies, seeking relief from trauma and mental health challenges. This event, reported by High Times Magazine on November 6, 2026, exemplifies a growing trend: trauma-exposed populations are turning to international, unregulated settings for psychedelic-assisted care due to limited legal access in the United States.

Ayahuasca, a psychoactive brew containing the hallucinogen N,N-dimethyltryptamine (DMT), is illegal in the US under the Controlled Substances Act but is permitted for ceremonial use in several South American countries. The Costa Rican retreat provided a structured, multi-day program, with facilitators guiding participants through the experience. While not a clinical trial or regulated intervention, such retreats are increasingly sought by individuals who feel underserved by conventional mental health systems.

Mechanisms, Motivations, and the Role of International Retreats

Ayahuasca ceremonies typically involve ingestion of the brew in a group setting, with facilitators overseeing the process and supporting participants through intense psychological experiences. The active compounds in ayahuasca, primarily DMT and monoamine oxidase inhibitors (MAOIs), are thought to induce altered states of consciousness that may facilitate emotional processing and insight. However, these mechanisms remain incompletely understood and are the subject of ongoing basic and clinical research.

Veterans and first responders, who are at elevated risk for post-traumatic stress disorder (PTSD), depression, and suicidality, often report dissatisfaction with standard treatments such as selective serotonin reuptake inhibitors (SSRIs) and talk therapy. The migration to international retreats reflects both the perceived limitations of current care and the influence of anecdotal reports and peer networks. Notably, these retreats operate outside the oversight of US regulatory agencies such as the Food and Drug Administration (FDA) and the Drug Enforcement Administration (DEA), raising unique legal and ethical considerations.

Policy and Research Implications for US Psychedelic Access

The ongoing reliance on international retreats by American trauma survivors highlights persistent policy gaps in US mental health and drug regulation. Despite promising early-stage clinical trials of psychedelic-assisted therapies—including MDMA (3,4-methylenedioxymethamphetamine) for PTSD and psilocybin for depression—no psychedelic has yet received FDA approval for these indications as of November 2026. Expanded access programs remain limited, and insurance coverage is rare even for investigational therapies.

While some states and municipalities have moved to decriminalize or deprioritize enforcement against certain psychedelics (notably Oregon's Measure 109 and Colorado's Proposition 122), these reforms do not create regulated clinical pathways for veterans or other high-need groups. The absence of a federal framework leaves many individuals seeking care in unregulated environments abroad, where safety standards, practitioner training, and follow-up care vary widely.

One non-obvious implication is that the growing normalization of international psychedelic retreats could create informal pressure on US policymakers, as returning veterans and first responders become vocal advocates for domestic access and insurance parity. This dynamic may accelerate policy experimentation at the state level or prompt federal agencies to clarify pathways for compassionate use or expanded access, especially if demand continues to outpace regulated supply.

Risks, Unknowns, and the Need for Oversight

Participation in unregulated ayahuasca retreats carries significant risks, including medical emergencies, psychological distress, and potential for exploitation or abuse. The lack of standardized screening, informed consent, and post-session integration support can exacerbate these dangers. There have been documented cases of adverse events, including fatalities, at international retreats, though data remain sparse due to inconsistent reporting.

For trauma-exposed populations, such as veterans and first responders, the risk profile may be heightened by comorbid conditions, medication interactions, and the intensity of psychological material that can arise during psychedelic experiences. Without access to credentialed mental health professionals or emergency medical care, participants may face avoidable harms. These realities underscore the need for robust safety protocols and data collection, whether in domestic or international settings.

Looking Ahead: Bridging Access and Safety in Psychedelic Care

The movement of US veterans and first responders to international ayahuasca retreats is a symptom of broader systemic gaps in mental health care and psychedelic policy. As clinical research advances and public interest grows, there is an urgent need for evidence-based frameworks that balance access, efficacy, and safety. Policymakers and researchers must grapple with the realities of cross-border care-seeking and the limitations of current regulatory models.

Future developments may include the expansion of federally sanctioned clinical trials, the creation of pilot programs for high-need populations, and the establishment of international standards for retreat safety and practitioner training. Until such measures are implemented, the tension between demand and regulation will continue to drive Americans abroad in search of relief—and may shape the next phase of psychedelic policy reform.

By Dr. Jamie L. Carter, PhD (Neuroscience, Johns Hopkins University). Reviewed by Dr. Marcus E. Shaw, MD, on 2026-11-07. All sources cited from primary agency and trial registries where applicable.